VR Logo

Pluristem Therapeutics Inc. (PSTI) download report


Healthcare | Biotechnology & Pharma Research

Pluristem Therapeutics Inc. (PSTI) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

IPO Date: 30-Jun-2003

Pres, CEO & Director: Mr. Yaacov Yanay

CFO, Treasurer & Sec.: Ms. Chen Franco-Yehuda

Listing: NASDAQ: PSTI

Country: Israel

Headquarters: Haifa,

Website: https://www.pluristem.com

Key Facts

Market cap: $40.43 Mln

Revenue (TTM): $0.23 Mln

Earnings (TTM): $-46.81 Mln

Cash: $61.98 Mln

Total Debt: $30.86 Mln

Insider's Holding: 7.28%

Liquidity: Low

52 Week range: $1.06 - 4.05

Shares outstanding: 32,347,600

10 Years Aggregate:

  • CFO: $-208.13 Mln
  • EBITDA: $-265.56 Mln
  • Net Profit: $-279.07 Mln

Stock Performance

Time Period Pluristem Therapeutics (PSTI) S&P BSE Sensex S&P Small-Cap 600
YTD-15.07-8.99-19.87
1 month-17.33-3.40-10.07
3 months-40.38-8.50-17.25
1 Year-69.150.89-18.01
3 Years-41.5410.415.62
5 Years-37.4011.435.60
10 Years-25.6411.779.69
As on 30-Jun-2022
Year Pluristem Therapeutics (PSTI) S&P Small-Cap 600 S&P BSE Sensex
2021-79.3525.2721.99
202079.449.5715.75
2019-50.0120.8614.38
2018-42.72-9.705.87
2017-3.5011.7327.91
201626.5524.741.95
2015-54.80-3.36-5.03